The safety of bimekizumab (Bimzelx) in long-term data is roughly in line with expectations from shorter-term studies. Adverse events during 2 or more years of treatment in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) were similar to previous data. The results come from a long-term extension of clinical studies. The BE OPTIMAL study followed 852 patients with active PsA who had not previously been treated with biologic DMARDs. Long-term data from the BE COMPLETE extension study showed that patients maintained a response to treatment with bimekizumab (160 mg every 4 weeks) for 52 weeks. An ACR 50 response at week 52 was achieved by 51.7% of patients with PsA and insufficient response to TNF inhibitors (n=267) and 40.6% of patients who switched from placebo (n=133). Bimekizumab was well tolerated with a safety profile similar to other biologics, except for a higher frequency of oral candidiasis.[1][2][3]